Some good news for a select few, with a rare "subset" of CRC

www.genomeweb.com/cancer/latest-orphan-status-entrectinib-crc-ignyta-continues-pursue-precision-rx-approach

Don't think link works;for those few with TrkA-positive,TrkB-positive,TrkC-positive,ROS1-positive and ALK-positive CRC (and non-small cell lung cancer with these characteristics) Entrectinib was just granted "orphan" status by FDA.......Tho this might involve no more than 2% of those Dxed with CRC,as stated in article. Should be other sources for this besides site cited.